GU Highlights – Setting a new standard in urothelial cancer

The data presented will undoubtedly change the first-line treatment of advanced urothelial carcinoma. In addition, interesting data were shown for radioligand 177Lutetium therapy in chemonaive metastatic castration-resistant prostate cancer.